Overview

A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer

Status:
Completed
Trial end date:
2019-01-14
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to investigate the safety of prexasertib in combination with other anti-cancer drugs (cisplatin or cetuximab) and radiation therapy in participants with locally advanced head and neck cancer. The study has two parts (A and B). Participants will only enroll in one part.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Cetuximab
Cisplatin